Leptin-R and its association with PI3K/AKT signaling pathway in papillary thyroid carcinoma

Endocrine-Related Cancer

Volumn 17, Issue 1, 2010, Pages 191-202

  Uddin, Shahab ^a   Bavi, Prashant ^a   Siraj, Abdul K ^a   Ahmed, Maqbool ^a   Al Rasheed, Maha ^a   Hussain, Azhar R ^a   Ahmed, Mohammed ^a   Amin, Tarek ^a   Alzahrani, Ali ^a   Al Dayel, Fouad ^a   Abubaker, Jehad ^a   Bu, Rong ^a   Al Kuraya, Khawla S ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; LEPTIN; LEPTIN RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL XL; PROTEIN KINASE B; X LINKED INHIBITOR OF APOPTOSIS;

ADULT; APOPTOSIS; ARTICLE; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CARCINOMA CELL; CELL PROLIFERATION; CONTROLLED STUDY; CYTOLYSIS; DISEASE FREE SURVIVAL; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GENE OVEREXPRESSION; GENE SILENCING; GROUPS BY AGE; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PHENOTYPE; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; THYROID CARCINOMA; TISSUE MICROARRAY; TUMOR VOLUME;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PAPILLARY; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEPTIN; LINKAGE (GENETICS); MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; ONCOGENE PROTEIN V-AKT; PROGNOSIS; RECEPTORS, LEPTIN; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; THYROID NEOPLASMS; TUMOR BURDEN; TUMOR CELLS, CULTURED;

EID: 77449155450     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1677/ERC-09-0153     Document Type: Article

References (49)

1. Abubaker J, Bavi P, Al-Harbi S, Ibrahim M, Siraj AK, Al-Sanea N, Abduljabbar A, Ashari LH, Alhomoud S, Al-Dayel F et al. 2008a Clinicopathological analysis of colorectal cancers with PIK3CA mutations in Middle Eastern population. Oncogene 27 3539-3545.
2. Abubaker J, Jehan Z, Bavi P, Sultana M, Al-Harbi S, Ibrahim M, Al-Nuaim A, Ahmed M, Amin T, Al-Fehaily M et al. 2008b Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population. Journal of Clinical Endocrinology and Metabolism 93 611-618.
3. Al-Eid HS AS 2004 Cancer Incidence Report Saudi Arabia 1999-2000. King Faisal Specialist Hospital and Research Centre. May 2004.
4. Al-Othaimeen AI, Al-Nozha M & Osman AK 2007 Obesity: an emerging problem in Saudi Arabia. Analysis of data from the National Nutrition Survey. Eastern Mediterranean Health Journal 13 441-448.
5. Badve S, Turbin D, Thorat MA, Morimiya A, Nielsen TO, Perou CM, Dunn S, Huntsman DG & Nakshatri H 2007 FOXA1 expression in breast cancer - correlation with luminal subtype A and survival. Clinical Cancer Research 13 4415-4421.
6. Bavi P, Jehan Z, Atizado V, Al-Dossari H, Al-Dayel F, Tulbah A, Amr SS, Sheikh SS, Ezzat A, El-Solh H et al. 2006 Prevalence of fragile histidine triad expression in tumors from Saudi Arabia: a tissue microarray analysis. Cancer Epidemiology, Biomarkers & Prevention 15 1708-1718.
7. Brunet A, Park J, Tran H, Hu LS, Hemmings BA & Greenberg ME 2001 Protein kinase SGK mediates survival signals by phosphorylating the forkhead transcription factor FKHRL1 (FOXO3a). Molecular and Cellular Biology 21 952-965.
8. Camp RL, Dolled-Filhart M & Rimm DL 2004 X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clinical Cancer Research 10 7252-7259.
9. Chen C, Chang YC, Liu CL, Chang KJ & Guo IC 2006 Leptin-induced growth of human ZR-75-1 breast cancer cells is associated with up-regulation of cyclin D1 and c-Myc and down-regulation of tumor suppressor p53 and p21WAF1/CIP1. Breast Cancer Research and Treatment 98 121-132.
10. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, Ohannesian JP, Marco CC, McKee LJ, Bauer TL et al. 1996 Serum immunoreactiveleptin concentrations in normal-weight and obese humans. New England Journal of Medicine 334 292-295.
11. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y & Greenberg ME 1997 Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91 231-241.
12. Davies L & Welch HG 2006 Increasing incidence of thyroid cancer in the United States, 1973-2002. Journal of the American Medical Association 295 2164-2167.
13. Garofalo C & Surmacz E 2006 Leptin and cancer. Journal of Cellular Physiology 207 12-22.
14. Grossman SR, Lyle S, Resnick MB, Sabo E, Lis RT, Rosinha E, Liu Q, Hsieh CC, Bhat G, Frackelton AR Jr et al. 2007 p66 Shc tumor levels show a strong prognostic correlation with disease outcome in stage IIA colon cancer. Clinical Cancer Research 13 5798-5804.
15. Hardwick JC, Van Den Brink GR, Offerhaus GJ, Van Deventer SJ & Peppelenbosch MP 2001 Leptin is a growth factor for colonic epithelial cells. Gastroenterology 121 79-90.
16. Hay ID 1990 Papillary thyroid carcinoma. Endocrinology and Metabolism Clinics of North America 19 545-576.
17. Hegyi K, Fulop K, Kovacs K, Toth S & Falus A 2004 Leptin-induced signal transduction pathways. Cell Biology International 28 159-169.
18. Hoda MR, Keely SJ, Bertelsen LS, Junger WG, Dharmasena D & Barrett KE 2007 Leptin acts as a mitogenic and antiapoptotic factor for colonic cancer cells. British Journal of Surgery 94 346-354.
19. Hong SJ, Kwon KW, Kim SG, Ko BM, Ryu CB, Kim YS, Moon JH, Cho JY, Lee JS, Lee MS et al. 2006 Variation in expression of gastric leptin according to differentiation and growth pattern in gastric adenocarcinoma. Cytokine 33 66-71.
20. Hu X, Juneja SC, Maihle NJ & Cleary MP 2002 Leptin - a growth factor in normal and malignant breast cells and for normal mammary gland development. Journal of the National Cancer Institute 94 1704-1711.
21. Hundahl SA, Fleming ID, Fremgen AM & Menck HR 1998 A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 (see commetns). Cancer 83 2638-2648.
22. Hussain AR, Al-Jomah NA, Siraj AK, Manogaran P, Al-Hussein K, Abubaker J, Platanias LC, Al-Kuraya KS & Uddin S 2007 Sanguinarine-dependent induction of apoptosis in primary effusion lymphoma cells. Cancer Research 67 3888-3897.
23. Hussain AR, Ahmed M, Al-Jomah NA, Khan AS, Manogaran P, Sultana M, Abubaker J, Platanias LC, Al-Kuraya KS & Uddin S 2008 Curcumin suppresses constitutive activation of nuclear factor-kappa B and requires functional Bax to induce apoptosis in Burkitt's lymphoma cell lines. Molecular Cancer Therapeutics 7 3318-3329.
24. Ishikawa M, Kitayama J & Nagawa H 2004 Enhanced expression of leptin and leptin receptor (OB-R) in human breast cancer. Clinical Cancer Research 10 4325-4331.
25. Janeckova R 2001 The role of leptin in human physiology and pathophysiology. Physiological Research 50 443-459.
26. Khoja TAM 2008 Cancer Incidence Among Gulf Cooperation Council States Nationals-2003, edn 2006, pp 37-44. Eds Gulf Center for Cancer Registration. Riyadh, Saudi Arabia: King Faisal Specialist Hospital & Research Centre.
27. Kim K, Visintin I, Alvero AB & Mor G 2009 Development and validation of a protein-based signature for the detection of ovarian cancer. Clinics in Laboratory Medicine 29 47-55.
28. Koda M, Sulkowska M, Kanczuga-Koda L, Surmacz E & Sulkowski S 2007a Overexpression of the obesity hormone leptin in human colorectal cancer. Journal of Clinical Pathology 60 902-906.
29. Koda M, Sulkowska M, Wincewicz A, Kanczuga-Koda L, Musiatowicz B, Szymanska M & Sulkowski S 2007b Expression of leptin, leptin receptor, and hypoxia-inducible factor 1 alpha in human endometrial cancer. Annals of the New York Academy of Sciences 1095 90-98.
30. Leonhardt U, Ritzel U, Schafer G, Becker W & Ramadori G 1998 Serum leptin levels in hypo- and hyperthyroidism. Journal of Endocrinology 157 75-79.
31. Loh KC, Greenspan FS, Gee L, Miller TR & Yeo PP 1997 Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients. Journal of Clinical Endocrinology and Metabolism 82 3553-3562.
32. Maccio A, Madeddu C, Massa D, Astara G, Farci D, Melis GB & Mantovani G 2008 Interleukin-6 and leptin as markers of energy metabolic changes in advanced ovarian cancer patients. Journal of Cellular and Molecular Medicine [in press].
33. McCarthy MM, Sznol M, DiVito KA, Camp RL, Rimm DL & Kluger HM 2005 Evaluating the expression and prognostic value of TRAIL-R1 and TRAIL-R2 in breast cancer. Clinical Cancer Research 11 5188-5194.
34. Ogunwobi OO & Beales IL 2007 The anti-apoptotic and growth stimulatory actions of leptin in human colon cancer cells involves activation of JNK mitogen activated protein kinase, JAK2 and PI3 kinase/Akt. International Journal of Colorectal Disease 22 401-409.
35. 2-terminal kinase activation. Endocrinology 147 4505-4516.
36. Osaki M, Oshimura M & Ito H 2004 PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 9 667-676.
37. Pan SY, Johnson KC, Ugnat AM, Wen SW & Mao Y 2004 Association of obesity and cancer risk in Canada. American Journal of Epidemiology 159 259-268.
38. Pfaffl MW,Georgieva TM, Georgiev IP, Ontsouka E, Hageleit M & Blum JW 2002 Real-time RT-PCR quantification of insulin-like growth factor (IGF)-1, IGF-1 receptor, IGF-2, IGF-2 receptor, insulin receptor, growth hormone receptor, IGF-binding proteins 1, 2 and 3 in the bovine species. Domestic Animal Endocrinology 22 91-102.
39. Raef H, Alfadhli E, Al-Hajjaj A, Malabu UH, Al-Sobhi S, Rifai A & Al Nuaim A 2008 High rate of persistent-recurrent disease among patients with differentiated thyroid cancer in Saudi Arabia: factors affecting nonremission. Annals of Saudi Medicine 28 277-281.
40. Saxena NK, Sharma D, Ding X, Lin S, Marra F, Merlin D & Anania FA 2007 Concomitant activation of the JAK/-STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer Research 67 2497-2507.
41. Sharma D, Saxena NK, Vertino PM & Anania FA 2006 Leptin promotes the proliferative response and invasiveness in human endometrial cancer cells by activating multiple signal-transduction pathways. Endocrine-Related Cancer 13 629-640.
42. Siironen P, Louhimo J, Nordling S, Ristimaki A, Maenpaa H, Haapiainen R & Haglund C 2005 Prognostic factors in papillary thyroid cancer: an evaluation of 601 consecutive patients. Tumour Biology 26 57-64.
43. Siraj A, Bavi P, Abubaker J, Jehan Z, Sultana M, Al-Dayel F, Al-Nuaim A, Alzahrani A, Ahmed M, Al-Sanea O et al. 2007 Genome-wide expression analysis of Middle Eastern papillary thyroid cancer reveals c-MET as a novel target for cancer therapy. Journal of Pathology 213 190-199.
44. Uddin S, Hussain AR, Siraj AK, Manogaran PS, Al-Jomah NA, Moorji A, Atizado V, Al-Dayel F, Belgaumi A, El-Solh H et al. 2006 Role of phosphatidylinositol 3′-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood 108 4178-4186.
45. Uddin S, Ahmed M, Bavi P, El-Sayed R, Al-Sanea N, AbdulJabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Hussain AR et al. 2008a Bortezomib (Velcade) induces p27Kip1 expression through S-phase kinase protein 2 degradation in colorectal cancer. Cancer Research 68 3379-3388.
46. Uddin S, Hussain A, Ahmed M, Belgaumi A, Al-Dayel F, Ajarim D, Bavi P & Al-Kuraya KS 2008b S-phase kinase protein 2 is an attractive therapeutic target in a subset of diffuse large B-cell lymphoma. Journal of Pathology 216 483-494.
47. Uddin S, Siraj AK, Al-Rasheed M, Ahmed M, Bu R, Myers JN, Al-Nuaim A, Al-Sobhi S, Al-Dayel F, Bavi P et al. 2008c Fatty acid synthase and AKT pathway signaling in a subset of papillary thyroid cancers. Journal of Clinical Endocrinology and Metabolism 93 4088-4097.
48. Zabeau L, Lavens D, Peelman F, Eyckerman S, Vande-kerckhove J & Tavernier J 2003 The ins and outs of leptin receptor activation. FEBS Letters 546 45-50.
49. Zimmermann-Belsing T, Brabant G, Holst JJ & Feldt-Rasmussen U 2003 Circulating leptin and thyroid dysfunction. European Journal of Endocrinology 149 257-271.